메뉴 건너뛰기
Antimicrobial Agents and Chemotherapy
Volumn 59, Issue 5, 2015, Pages 2842-2848
β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models
Author keywords

[No Author keywords available]
Indexed keywords

AMPICILLIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CEFTAROLINE; DAPTOMYCIN; ERTAPENEM; ANTIINFECTIVE AGENT; BETA LACTAM; CEPHALOSPORIN DERIVATIVE; VANCOMYCIN;
EID: 84931260904     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00053-15     Document Type: Article
Times cited : (42)
References (53)
  • 1
    • 84870946642 scopus 로고    scopus 로고
    • Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010
    • Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S. 2013. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 34:1-14. http://dx.doi.org/10.1086/668770.
    • (2013) Infect Control Hosp Epidemiol , vol.34 , pp. 1-14
    • Sievert, D.M.1    Ricks, P.2    Edwards, J.R.3    Schneider, A.4    Patel, J.5    Srinivasan, A.6    Kallen, A.7    Limbago, B.8    Fridkin, S.9
  • 2
    • 84864319279 scopus 로고    scopus 로고
    • Antibiotic resistance and virulence traits in clinical and environmental Enterococcus faecalis and Enterococcus faecium isolates
    • Rathnayake IU, Hargreaves M, Huygens F. 2012. Antibiotic resistance and virulence traits in clinical and environmental Enterococcus faecalis and Enterococcus faecium isolates. Syst Appl Microbiol 35:326-333. http://dx.doi.org/10.1016/j.syapm.2012.05.004.
    • (2012) Syst Appl Microbiol , vol.35 , pp. 326-333
    • Rathnayake, I.U.1    Hargreaves, M.2    Huygens, F.3
  • 5
    • 0037190708 scopus 로고    scopus 로고
    • Health and economic outcomes of vancomycin-resistant enterococci
    • Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. 2002. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 162:2223-2228. http://dx.doi.org/10.1001/archinte.162.19.2223.
    • (2002) Arch Intern Med , vol.162 , pp. 2223-2228
    • Carmeli, Y.1    Eliopoulos, G.2    Mozaffari, E.3    Samore, M.4
  • 6
    • 25844530748 scopus 로고    scopus 로고
    • Infective endocarditis: Diagnosis, antimicrobial therapy, and management of complications: A statement for healthcare professionals from the Comm. on Rheumatic Fever, Endocarditis, and Kawasaki Dis., Cncl. on Cardiovasc. Dis. in the Young, and the Councils on Clin. Cardiol., Stroke, and Cardiovasc. Surg. and Anesthesia, Amer. Heart Association: Endorsed by the Infectious Diseases Society of Amer
    • Baddour LM, Wilson WR, Bayer AS, Fowler VG, Jr, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111:e394-e434. http://dx.doi.org/10.1161/CIRCULATIONAHA.105.165564.
    • (2005) Circulation , vol.111 , pp. e394-e434
    • Baddour, L.M.1    Wilson, W.R.2    Bayer, A.S.3    Fowler, V.G.4    Bolger, A.F.5    Levison, M.E.6    Ferrieri, P.7    Gerber, M.A.8    Tani, L.Y.9    Gewitz, M.H.10    Tong, D.C.11    Steckelberg, J.M.12    Baltimore, R.S.13    Shulman, S.T.14    Burns, J.C.15    Falace, D.A.16    Newburger, J.W.17    Pallasch, T.J.18    Takahashi, M.19    Taubert, K.A.20    more..
  • 8
    • 33748192486 scopus 로고    scopus 로고
    • Linezolid for the treatment of patients with endocarditis: A systematic review of the published evidence
    • Falagas ME, Manta KG, Ntziora F, Vardakas KZ. 2006. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother 58:273-280. http://dx.doi.org/10.1093/jac/dkl219.
    • (2006) J Antimicrob Chemother , vol.58 , pp. 273-280
    • Falagas, M.E.1    Manta, K.G.2    Ntziora, F.3    Vardakas, K.Z.4
  • 9
    • 84884949156 scopus 로고    scopus 로고
    • A current perspective on daptomycin for the clinical microbiologist
    • Humphries RM, Pollett S, Sakoulas G. 2013. A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev 26:759-780. http://dx.doi.org/10.1128/CMR.00030-13.
    • (2013) Clin Microbiol Rev , vol.26 , pp. 759-780
    • Humphries, R.M.1    Pollett, S.2    Sakoulas, G.3
  • 10
    • 84865425113 scopus 로고    scopus 로고
    • Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins
    • Pogliano J, Pogliano N, Silverman JA. 2012. Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins. J Bacteriol 194:4494-4504. http://dx.doi.org/10.1128/JB.00011-12.
    • (2012) J Bacteriol , vol.194 , pp. 4494-4504
    • Pogliano, J.1    Pogliano, N.2    Silverman, J.A.3
  • 11
    • 33748946749 scopus 로고    scopus 로고
    • Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: Comparison with cationic antimicrobial peptides and lipopeptides
    • Straus SK, Hancock RE. 2006. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim Biophys Acta 1758:1215-1223. http://dx.doi.org/10.1016/j.bbamem.2006.02.009.
    • (2006) Biochim Biophys Acta , vol.1758 , pp. 1215-1223
    • Straus, S.K.1    Hancock, R.E.2
  • 12
    • 0035144849 scopus 로고    scopus 로고
    • Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations
    • Akins RL, Rybak MJ. 2001. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 45:454-459. http://dx.doi.org/10.1128/AAC.45.2.454-459.2001.
    • (2001) Antimicrob Agents Chemother , vol.45 , pp. 454-459
    • Akins, R.L.1    Rybak, M.J.2
  • 13
    • 84861135687 scopus 로고    scopus 로고
    • Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations
    • Hall AD, Steed ME, Arias CA, Murray BE, Rybak MJ. 2012. Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 56:3174-3180. http://dx.doi.org/10.1128/AAC.06439-11.
    • (2012) Antimicrob Agents Chemother , vol.56 , pp. 3174-3180
    • Hall, A.D.1    Steed, M.E.2    Arias, C.A.3    Murray, B.E.4    Rybak, M.J.5
  • 15
    • 84899513035 scopus 로고    scopus 로고
    • Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: Summary of 8 years of a Worldwide Surveillance Programme (2005-2012)
    • Sader HS, Farrell DJ, Flamm RK, Jones RN. 2014. Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012). Int J Antimicrob Agents 43:465-469. http://dx.doi.org/10.1016/j.ijantimicag.2014.01.018.
    • (2014) Int J Antimicrob Agents , vol.43 , pp. 465-469
    • Sader, H.S.1    Farrell, D.J.2    Flamm, R.K.3    Jones, R.N.4
  • 18
    • 84864390248 scopus 로고    scopus 로고
    • Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: Revisiting daptomycin breakpoints
    • Munita JM, Panesso D, Diaz L, Tran TT, Reyes J, Wanger A, Murray BE, Arias CA. 2012. Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints. Antimicrob Agents Chemother 56:4354-4359. http://dx.doi.org/10.1128/AAC.00509-12.
    • (2012) Antimicrob Agents Chemother , vol.56 , pp. 4354-4359
    • Munita, J.M.1    Panesso, D.2    Diaz, L.3    Tran, T.T.4    Reyes, J.5    Wanger, A.6    Murray, B.E.7    Arias, C.A.8
  • 19
    • 84868018494 scopus 로고    scopus 로고
    • Genotypic and phenotypic evaluation of the evolution of high-level daptomycin nonsusceptibility in vancomycin-resistant Enterococcus faecium
    • Humphries RM, Kelesidis T, Tewhey R, Rose WE, Schork N, Nizet V, Sakoulas G. 2012. Genotypic and phenotypic evaluation of the evolution of high-level daptomycin nonsusceptibility in vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 56:6051-6053. http://dx.doi.org/10.1128/AAC.01318-12.
    • (2012) Antimicrob Agents Chemother , vol.56 , pp. 6051-6053
    • Humphries, R.M.1    Kelesidis, T.2    Tewhey, R.3    Rose, W.E.4    Schork, N.5    Nizet, V.6    Sakoulas, G.7
  • 20
    • 84912121163 scopus 로고    scopus 로고
    • Heterogeneity of mprF sequences in methicillin-resistant Staphylococcus aureus clinical isolates: Role in cross-resistance between daptomycin and host defense antimicrobial peptides
    • Bayer AS, Mishra NN, Sakoulas G, Nonejuie P, Nast CC, Pogliano J, Chen KT, Ellison SN, Yeaman MR, Yang SJ. 2014. Heterogeneity of mprF sequences in methicillin-resistant Staphylococcus aureus clinical isolates: role in cross-resistance between daptomycin and host defense antimicrobial peptides. Antimicrob Agents Chemother 58:7462-7467. http://dx.doi.org/10.1128/AAC.03422-14.
    • (2014) Antimicrob Agents Chemother , vol.58 , pp. 7462-7467
    • Bayer, A.S.1    Mishra, N.N.2    Sakoulas, G.3    Nonejuie, P.4    Nast, C.C.5    Pogliano, J.6    Chen, K.T.7    Ellison, S.N.8    Yeaman, M.R.9    Yang, S.J.10
  • 21
    • 84899039263 scopus 로고    scopus 로고
    • Emergence of daptomycin resistance in daptomycin-naive rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms
    • Mishra NN, Yang SJ, Chen L, Muller C, Saleh-Mghir A, Kuhn S, Peschel A, Yeaman MR, Nast CC, Kreiswirth BN, Cremieux AC, Bayer AS. 2013. Emergence of daptomycin resistance in daptomycin-naive rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms. PLoS One 8:e71151. http://dx.doi.org/10.1371/journal.pone.0071151.
    • (2013) PLoS One , vol.8
    • Mishra, N.N.1    Yang, S.J.2    Chen, L.3    Muller, C.4    Saleh-Mghir, A.5    Kuhn, S.6    Peschel, A.7    Yeaman, M.R.8    Nast, C.C.9    Kreiswirth, B.N.10    Cremieux, A.C.11    Bayer, A.S.12
  • 22
    • 84866912756 scopus 로고    scopus 로고
    • Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin-naive bacteremic patients
    • Mishra NN, Bayer AS, Moise PA, Yeaman MR, Sakoulas G. 2012. Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin-naive bacteremic patients. J Infect Dis 206:1160-1167. http://dx.doi.org/10.1093/infdis/jis482.
    • (2012) J Infect Dis , vol.206 , pp. 1160-1167
    • Mishra, N.N.1    Bayer, A.S.2    Moise, P.A.3    Yeaman, M.R.4    Sakoulas, G.5
  • 23
    • 84904569642 scopus 로고    scopus 로고
    • Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model
    • Hall Snyder A, Werth BJ, Barber KE, Sakoulas G, Rybak MJ. 2014. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model. J Antimicrob Chemother 56:2148-2154. http://dx.doi.org/10.1093/jac/dku113.
    • (2014) J Antimicrob Chemother , vol.56 , pp. 2148-2154
    • Hall Snyder, A.1    Werth, B.J.2    Barber, K.E.3    Sakoulas, G.4    Rybak, M.J.5
  • 24
    • 84862965144 scopus 로고    scopus 로고
    • Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium
    • Sakoulas G, Bayer AS, Pogliano J, Tsuji BT, Yang SJ, Mishra NN, Nizet V, Yeaman MR, Moise PA. 2012. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 56:838-844. http://dx.doi.org/10.1128/AAC.05551-11.
    • (2012) Antimicrob Agents Chemother , vol.56 , pp. 838-844
    • Sakoulas, G.1    Bayer, A.S.2    Pogliano, J.3    Tsuji, B.T.4    Yang, S.J.5    Mishra, N.N.6    Nizet, V.7    Yeaman, M.R.8    Moise, P.A.9
  • 25
    • 84896867461 scopus 로고    scopus 로고
    • Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium
    • Sakoulas G, Rose W, Nonejuie P, Olson J, Pogliano J, Humphries R, Nizet V. 2014. Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 58:1494-1500. http://dx.doi.org/10.1128/AAC.02274-13.
    • (2014) Antimicrob Agents Chemother , vol.58 , pp. 1494-1500
    • Sakoulas, G.1    Rose, W.2    Nonejuie, P.3    Olson, J.4    Pogliano, J.5    Humphries, R.6    Nizet, V.7
  • 26
    • 84880268579 scopus 로고    scopus 로고
    • Treatment of high-level gentamicin-resistant Enterococcus faecalis endocarditis with daptomycin plus ceftaroline
    • Sakoulas G, Nonejuie P, Nizet V, Pogliano J, Crum-Cianflone N, Haddad F. 2013. Treatment of high-level gentamicin-resistant Enterococcus faecalis endocarditis with daptomycin plus ceftaroline. Antimicrob Agents Chemother 57:4042-4045. http://dx.doi.org/10.1128/AAC.02481-12.
    • (2013) Antimicrob Agents Chemother , vol.57 , pp. 4042-4045
    • Sakoulas, G.1    Nonejuie, P.2    Nizet, V.3    Pogliano, J.4    Crum-Cianflone, N.5    Haddad, F.6
  • 27
    • 84868021561 scopus 로고    scopus 로고
    • Combination therapy with ampicillin and daptomycin for treatment of Enterococcus faecalis endocarditis
    • Sierra-Hoffman M, Iznaola O, Goodwin M, Mohr J. 2012. Combination therapy with ampicillin and daptomycin for treatment of Enterococcus faecalis endocarditis. Antimicrob Agents Chemother 56:6064. http://dx.doi.org/10.1128/AAC.01760-12.
    • (2012) Antimicrob Agents Chemother , vol.56 , pp. 6064
    • Sierra-Hoffman, M.1    Iznaola, O.2    Goodwin, M.3    Mohr, J.4
  • 28
    • 84930509964 scopus 로고    scopus 로고
    • β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium
    • 1 February
    • Smith JR, Barber KE, Raut A, Aboutaleb M, Sakoulas G, Rybak MJ. 1 February 2015. β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother http://dx.doi.org/10.1093/jac/dkv007.
    • (2015) J Antimicrob Chemother
    • Smith, J.R.1    Barber, K.E.2    Raut, A.3    Aboutaleb, M.4    Sakoulas, G.5    Rybak, M.J.6
  • 29
    • 33749534709 scopus 로고    scopus 로고
    • Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers
    • Benvenuto M, Benziger DP, Yankelev S, Vigliani G. 2006. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 50:3245-3249. http://dx.doi.org/10.1128/AAC.00247-06.
    • (2006) Antimicrob Agents Chemother , vol.50 , pp. 3245-3249
    • Benvenuto, M.1    Benziger, D.P.2    Yankelev, S.3    Vigliani, G.4
  • 30
    • 78649464718 scopus 로고    scopus 로고
    • Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: Rationale for improved antimethicillin-resistant Staphylococcus aureus activity
    • Drusano GL. 2010. Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved antimethicillin-resistant Staphylococcus aureus activity. J Antimicrob Chemother 65(Suppl 4):iv33-iv39. http://dx.doi.org/10.1093/jac/dkq253.
    • (2010) J Antimicrob Chemother , vol.65 , pp. iv33-iv39
    • Drusano, G.L.1
  • 33
    • 84894471385 scopus 로고    scopus 로고
    • Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: Evaluation of the impact of renal impairment
    • Soto E, Shoji S, Muto C, Tomono Y, Marshall S. 2014. Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment. Br J Clin Pharmacol 77:509-521. http://dx.doi.org/10.1111/bcp.12232.
    • (2014) Br J Clin Pharmacol , vol.77 , pp. 509-521
    • Soto, E.1    Shoji, S.2    Muto, C.3    Tomono, Y.4    Marshall, S.5
  • 34
    • 84875422878 scopus 로고    scopus 로고
    • Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers
    • Wiskirchen DE, Housman ST, Quintiliani R, Nicolau DP, Kuti JL. 2013. Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers. Pharmacotherapy 33:266-274. http://dx.doi.org/10.1002/phar.1197.
    • (2013) Pharmacotherapy , vol.33 , pp. 266-274
    • Wiskirchen, D.E.1    Housman, S.T.2    Quintiliani, R.3    Nicolau, D.P.4    Kuti, J.L.5
  • 35
    • 0021832112 scopus 로고
    • In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives
    • Blaser J. 1985. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J Antimicrob Chemother 15(Suppl A):125-130.
    • (1985) J Antimicrob Chemother , vol.15 , pp. 125-130
    • Blaser, J.1
  • 36
    • 0037378761 scopus 로고    scopus 로고
    • Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects
    • Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. 2003. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 47:1318-1323. http://dx.doi.org/10.1128/AAC.47.4.1318-1323.2003.
    • (2003) Antimicrob Agents Chemother , vol.47 , pp. 1318-1323
    • Dvorchik, B.H.1    Brazier, D.2    DeBruin, M.F.3    Arbeit, R.D.4
  • 39
    • 0035028433 scopus 로고    scopus 로고
    • Penicillin-binding protein 5 and expression of ampicillin resistance in Enterococcus faecium
    • Rice LB, Carias LL, Hutton-Thomas R, Sifaoui F, Gutmann L, Rudin SD. 2001. Penicillin-binding protein 5 and expression of ampicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother 45:1480-1486. http://dx.doi.org/10.1128/AAC.45.5.1480-1486.2001.
    • (2001) Antimicrob Agents Chemother , vol.45 , pp. 1480-1486
    • Rice, L.B.1    Carias, L.L.2    Hutton-Thomas, R.3    Sifaoui, F.4    Gutmann, L.5    Rudin, S.D.6
  • 41
    • 84902539671 scopus 로고    scopus 로고
    • In vitro synergy of ampicillin with gentamicin, ceftriaxone and ciprofloxacin against Enterococcus faecalis
    • Liao CH, Huang YT, Tsai HY, Hsueh PR. 2014. In vitro synergy of ampicillin with gentamicin, ceftriaxone and ciprofloxacin against Enterococcus faecalis. Int J Antimicrob Agents 44:85-86. http://dx.doi.org/10.1016/j.ijantimicag.2014.03.011.
    • (2014) Int J Antimicrob Agents , vol.44 , pp. 85-86
    • Liao, C.H.1    Huang, Y.T.2    Tsai, H.Y.3    Hsueh, P.R.4
  • 42
    • 0029133791 scopus 로고
    • Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis
    • Mainardi JL, Gutmann L, Acar JF, Goldstein FW. 1995. Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis. Antimicrob Agents Chemother 39:1984-1987. http://dx.doi.org/10.1128/AAC.39.9.1984.
    • (1995) Antimicrob Agents Chemother , vol.39 , pp. 1984-1987
    • Mainardi, J.L.1    Gutmann, L.2    Acar, J.F.3    Goldstein, F.W.4
  • 44
    • 84922473318 scopus 로고    scopus 로고
    • Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE
    • Werth BJ, Barber KE, Tran KN, Nonejuie P, Sakoulas G, Pogliano J, Rybak MJ. 2015. Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE. J Antimicrob Chemother 70:489-493. http://dx.doi.org/10.1093/jac/dku386.
    • (2015) J Antimicrob Chemother , vol.70 , pp. 489-493
    • Werth, B.J.1    Barber, K.E.2    Tran, K.N.3    Nonejuie, P.4    Sakoulas, G.5    Pogliano, J.6    Rybak, M.J.7
  • 46
    • 0030004907 scopus 로고    scopus 로고
    • Penicillin-binding protein 5 as an inhibitory target of cefozopran in Enterococcus faecalis
    • Tsuchimori N, Okonogi K. 1996. Penicillin-binding protein 5 as an inhibitory target of cefozopran in Enterococcus faecalis. J Antimicrob Chemother 37:605-609. http://dx.doi.org/10.1093/jac/37.3.605.
    • (1996) J Antimicrob Chemother , vol.37 , pp. 605-609
    • Tsuchimori, N.1    Okonogi, K.2
  • 48
    • 0031686776 scopus 로고    scopus 로고
    • Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils
    • Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI. 1998. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 42:2206-2214.
    • (1998) Antimicrob Agents Chemother , vol.42 , pp. 2206-2214
    • Turner, J.1    Cho, Y.2    Dinh, N.N.3    Waring, A.J.4    Lehrer, R.I.5
  • 49
    • 84906081308 scopus 로고    scopus 로고
    • Comparative mechanistic studies of brilacidin, daptomycin and the antimicrobial peptide LL16
    • Mensa B, Howell GL, Scott R, DeGrado WF. 2014. Comparative mechanistic studies of brilacidin, daptomycin and the antimicrobial peptide LL16. Antimicrob Agents Chemother 58:5136-5145. http://dx.doi.org/10.1128/AAC.02955-14.
    • (2014) Antimicrob Agents Chemother , vol.58 , pp. 5136-5145
    • Mensa, B.1    Howell, G.L.2    Scott, R.3    DeGrado, W.F.4
  • 51
    • 84872041928 scopus 로고    scopus 로고
    • Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model
    • Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ. 2013. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 57:66-73. http://dx.doi.org/10.1128/AAC.01586-12.
    • (2013) Antimicrob Agents Chemother , vol.57 , pp. 66-73
    • Werth, B.J.1    Sakoulas, G.2    Rose, W.E.3    Pogliano, J.4    Tewhey, R.5    Rybak, M.J.6
  • 52
    • 0034992653 scopus 로고    scopus 로고
    • Ertapenem: A new carbapenem
    • Odenholt I. 2001. Ertapenem: a new carbapenem. Expert Opin Invest Drugs 10:1157-1166. http://dx.doi.org/10.1517/13543784.10.6.1157.
    • (2001) Expert Opin Invest Drugs , vol.10 , pp. 1157-1166
    • Odenholt, I.1
  • 53
    • 84875197485 scopus 로고    scopus 로고
    • Current pharmacotherapy options for osteomyelitis: Convergences, divergences and lessons to be drawn
    • Senneville E, Nguyen S. 2013. Current pharmacotherapy options for osteomyelitis: convergences, divergences and lessons to be drawn. Expert Opin Pharmacother 14:723-734. http://dx.doi.org/10.1517/14656566.2013.780596.
    • (2013) Expert Opin Pharmacother , vol.14 , pp. 723-734
    • Senneville, E.1    Nguyen, S.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.